The core idea is deceptively simple: if the immune system clears foreign nanoparticles before they can do their work, disguise them as something the body already tolerates. The most extensively studied disguise is the red blood cell membrane. Human erythrocytes circulate for roughly 120 days, largely because they display CD47, a surface protein that transmits a “don’t eat me” signal to macrophages, along with band 3 and glycophorins that suppress opsonization and complement activation. When nanoparticles are cloaked in RBC membrane, they inherit these properties, dramatically extending circulation half-life and protecting encapsulated mRNA or peptide antigens from serum nucleases and proteases. Hybrid RBC-lipid nanoparticle platforms have shown improved mRNA protection, prolonged antigen expression, and enhanced dendritic cell uptake, while RBC-coated PLGA particles loaded with tumor peptides have generated stronger cytotoxic T lymphocyte responses in preclinical tumor models.

Exosomes, the nanoscale vesicles between 30 and 150 nanometers that cells naturally secrete to communicate with one another, offer a second biomimetic strategy with a different immunological personality. Their membranes carry tetraspanins and integrins that promote selective uptake by dendritic cells, and their origin matters enormously. Tumor-derived exosomes ferry a broad repertoire of tumor-associated antigens and neoantigens that mirror the parental tumor, but they can also smuggle immunosuppressive cargo such as PD-L1, TGF-beta, and regulatory microRNAs that blunt T-cell responses. Dendritic cell-derived exosomes, by contrast, come pre-loaded with MHC-peptide complexes and CD80/CD86 co-stimulatory molecules capable of priming both CD4 and CD8 T cells without requiring live dendritic cells. The catch is manufacturing: donor heterogeneity, variable cargo composition, and purification methods that differ wildly in yield and purity make GMP-grade standardization a formidable barrier.

Fully synthetic coatings sidestep some of that unpredictability. Artificial lipid bilayers and polymer shells can be tuned for antigen density, ligand spacing, endosomal escape, and release kinetics, and they can be functionalized with mannose for dendritic cell targeting, TLR agonists such as CpG or MPLA for innate activation, or checkpoint modulators like anti-PD-1 peptides. pH-sensitive and enzyme-responsive linkers now allow cargo release triggered by the acidic, enzyme-rich tumor microenvironment itself. Perhaps most striking are artificial antigen-presenting cells, polymeric scaffolds displaying MHC-I-peptide complexes and co-stimulatory ligands, which have outperformed natural dendritic cells at activating antigen-specific CD8 T cells both in vitro and in vivo. Hybrid systems that combine RBC membranes with exosomal or tumor-derived components aim to capture the best of both worlds: long circulation plus tumor homing and cross-presentation.

On the payload side, the review distinguishes two complementary modalities. Peptide nanovaccines deliver defined tumor epitopes chosen for strong MHC binding and minimal expression in healthy tissue, with neoantigens prioritized over shared antigens to avoid central tolerance. The authors’ own prior work illustrates the approach: survivin epitope variants delivered in PLGA nanoparticles drove potent CTL responses, BCMA peptide-loaded nanoparticles enhanced dendritic cell delivery in multiple myeloma models, and STEAP peptide nanovaccines inhibited tumor growth in vivo. mRNA nanovaccines take the opposite tack, encoding full-length antigens or multiple epitopes so that dendritic cells manufacture the antigen themselves, activating both CD4 and CD8 arms. Because mRNA does not integrate into the genome and carries intrinsic adjuvanticity through TLR3, TLR7/8, and RIG-I sensing, it offers a favorable safety profile, though poor endosomal escape and dose-dependent inflammation remain stubborn bottlenecks.

The COVID-19 pandemic supplied an unplanned clinical laboratory for these questions. The global mRNA-LNP rollout revealed that reactogenicity is dose-dependent, driven by innate recognition of ionizable lipids and mRNA structures, and that maximal inflammation does not equal optimal immune priming. Subtle structural differences in ionizable lipids markedly alter endosomal escape, biodistribution, and cytokine induction. For oncology, where patients are often immunosuppressed with altered pharmacokinetics, these lessons argue for individualized dose optimization, careful immune monitoring, and lipid engineering tailored specifically to cancer vaccination rather than borrowed wholesale from infectious disease.

Personalization is where the field is converging. Next-generation sequencing, mass spectrometry-based immunopeptidomics, and AI-guided epitope prediction now allow neoantigen discovery pipelines that move from tumor biopsy to individualized vaccine design in clinically relevant timelines. Autologous platforms go further, using patient-derived RBC, leukocyte, tumor cell, or exosome membranes so that even the nanoparticle surface reflects the patient’s biology, with tumor membrane coatings enabling homotypic binding to the originating cancer. The clinical signal is already visible: in the phase II KEYNOTE-942 trial, the personalized mRNA vaccine mRNA-4157 combined with pembrolizumab reduced recurrence risk by 44 percent and extended median progression-free survival from 16 to 23 months in resected high-risk melanoma, while BioNTech’s BNT111, targeting four melanoma-associated antigens, has demonstrated induction of both new and boosted pre-existing T-cell responses, albeit with a modest objective response rate that underscores interpatient variability.

Combination strategies may prove decisive. Biomimetic nanovaccines can prime T cells before checkpoint blockade, and sequencing studies suggest priming before PD-1 or CTLA-4 inhibition consistently outperforms simultaneous delivery. Co-delivery of antigens with TLR7/8, TLR9, or STING agonists within the same vesicle synchronizes innate and adaptive activation, while macrophage-targeted formulations can repolarize immunosuppressive M2 tumor-associated macrophages toward a pro-inflammatory M1 phenotype. Radiotherapy adds another layer, inducing immunogenic cell death that releases tumor antigens and damage-associated molecular patterns, activating the cGAS-STING pathway, and in rare but increasingly frequent cases producing abscopal responses in which nanovaccine-amplified immunity attacks metastases far from the irradiated site.

The translational obstacles are nonetheless sobering. Every personalized batch requires individualized sequencing, formulation, and quality control under time pressure dictated by fast-growing tumors. Patient-derived materials resist standardization, regulatory classification is murky because these products straddle biologics, cell therapies, and devices, and cold-chain logistics complicate distribution. The authors argue that modular microfluidic manufacturing, AI- and large-language-model-assisted neoantigen design, machine learning models that predict optimal nanoparticle physicochemistry, computer vision quality control, and digital twins of production pipelines could compress timelines and enforce batch consistency. Adaptive trial designs, including N-of-1 and Bayesian schemes, may be needed to evaluate vaccines that are by definition unique to each recipient, while immune-related response criteria replace conventional RECIST measurements that miss immunotherapy’s delayed kinetics.

What emerges from the review is a field in transition from clever chemistry to systems engineering. The mechanistic questions remain open, including how specific membrane compositions steer nanoparticles toward cross-presenting cDC1 dendritic cells versus degradative macrophage pathways, and which glycan signatures determine whether a coating stimulates or tolerizes. But the trajectory is clear: biomimetic coatings that borrow the body’s own camouflage, payloads scripted from each tumor’s mutanome, and AI-driven optimization loops that connect antigen discovery, formulation, manufacturing, and clinical feedback are converging into a unified platform. If the manufacturing and regulatory bottlenecks can be solved, the cancer vaccine may finally graduate from decades of sporadic promise into a routine pillar of precision oncology.

Subject of Research: Biomimetic and personalized nanovaccine platforms for cancer immunotherapy

Article Title: Biomimetic and personalized nanovaccines in cancer immunotherapy: Design innovations, translational challenges, and future directions

Article References: Xu, S., Yang, H., Minev, B., & Ma, W. (2026). Biomimetic and personalized nanovaccines in cancer immunotherapy: Design innovations, translational challenges, and future directions. Journal of Advanced Research, 88, 1137-1158. https://doi.org/10.1016/j.jare.2026.01.070

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.01.070

Keywords: nanovaccines, cancer immunotherapy, biomimetic nanoparticles, mRNA vaccines, neoantigens, red blood cell membrane, exosomes, lipid nanoparticles, immune checkpoint blockade, dendritic cells, personalized medicine, STING agonists